• PDF: Delivered by email usually within 12 to 24 UK business hours.

National Institutes of Health (NIH) - Developmental Therapeutics Review
Q4 2010

National Institutes of Health (NIH) - Developmental Therapeutics Review Q4 2010

National Institutes of Health (NIH) - Developmental Therapeutics Review - Q4 2010

Summary

Global Market Directs pharmaceuticals report, "National Institutes of Health (NIH) - Developmental Therapeutics Review - Q4 2010" provides data on the companys research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Directs proprietary databases, Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Directs team.

Scope

  • National Institutes of Health (NIH) - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of National Institutes of Health (NIH) human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of National Institutes of Health (NIH) with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the National Institutes of Health (NIH)s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate National Institutes of Health (NIH)s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of National Institutes of Health (NIH) in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the National Institutes of Health (NIH)s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with National Institutes of Health (NIH).
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of National Institutes of Health (NIH) and identify potential opportunities in those areas.
  • National Institutes of Health (NIH) Snapshot
    • National Institutes of Health (NIH) Overview
    • Key Information
    • Key Facts
    • National Institutes of Health (NIH) - Research and Development Overview
    • Key Therapeutic Areas
    • National Institutes of Health (NIH) - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • National Institutes of Health (NIH) - Pipeline Products Glance
    • National Institutes of Health (NIH) Clinical Stage Pipeline Products
    • Phase II Products/Combination Treatment Modalities
    • National Institutes of Health (NIH)-Early Stage Pipeline Products
    • Pre-Clinical Products/Combination Treatment Modalities
    • Discovery Products/Combination Treatment Modalities
    • National Institutes of Health (NIH) - Drug Profiles
    • Florbetapir F 18
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Inositol
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Hepatitis C Virus Clone, Strain HC-TN program
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • HGC-1
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • IGFBP-3
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • Isac
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • PB-39B
    • Product Description
    • Mechanism of Action
    • R&D Progress
    • National Institutes of Health (NIH) - Pipeline Analysis
    • National Institutes of Health (NIH) - Pipeline Products by Therapeutic Class
    • National Institutes of Health (NIH) Pipeline Products By Target
    • National Institutes of Health (NIH) - Pipeline Products by Route of Administration
    • National Institutes of Health (NIH) - Pipeline Products by Molecule Type
    • National Institutes of Health (NIH) - Dormant Projects
    • National Institutes of Health (NIH) - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
    • Financial Deals Landscape
    • Financial Deals Landscape
    • National Institutes of Health (NIH), Deals Volume Summary, 2004 to YTD 2010
    • National Institutes of Health (NIH), Deals Summary By Region, 2004 to YTD 2010
    • National Institutes of Health (NIH), Deals Summary, 2004 to YTD 2010
    • National Institutes of Health (NIH) Detailed Deal Summary
    • Enzo Biochem Enters Into Co-Development Agreement With National Institutes of Health
    • Inovio Biomedical Enters Into Research Agreement With Vaccine Research Center
    • Amsterdam Molecular Therapeutics Enters Into Co-Development Agreement With National Institutes of Health
    • Minster Pharmaceuticals Enters Into Research Agreement With National Institutes Of Health
    • Chaperone Technologies Enters Into Co-Development Agreement With National Institutes Of Health
    • MedImmune Enters Into Co-Development Agreement With National Institutes of Health
    • Crucell Extends Research Agreement With NIH
    • GenVec Enters Into Agreement With Vaccine Research Center
    • Athersys Enters Into Co-Development Agreement With The National Institutes Of Health
    • Licensing Agreements
    • Sequella Amends Licensing Agreement With NIH
    • Repros Amends Licensing Agreement With National Institutes
    • Can-Fite BioPharma Enters Into A Licensing Agreement With Leiden University And NIH
    • Theranostics Health Enters Into Licensing Agreement With National Institutes Of Health
    • NIH Extends Licensing Agreement with Genomatix Software
    • NeoPharm Enters Into Licensing Agreement With National Institute Of Health
    • GenVec Enters Into Licensing Agreement With Vaccine Research Center
    • Tigris Pharmaceuticals Enters Into Licensing Agreement With National Institutes Of Health
    • Axxam Enters Into Licensing Agreement With National Institutes of Health
    • Panacea Biotec Enters Into Licensing Agreement With National Institute of Health
    • Crucell Enters Into Licensing Agreement With NIH
    • GenVec Enters Into Licensing Agreement With National Institutes of Health
    • Targeted Genetics Enters Into Licensing Agreement With NIH
    • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer
  • List of Tables
    • National Institutes of Health (NIH) - Pipeline by Therapy Area and Indication, 2010
    • National Institutes of Health (NIH) - Pipeline by Stage of Development, 2010
    • National Institutes of Health (NIH) - Monotherapy Products in Pipeline, 2010
    • National Institutes of Health (NIH) - Phase II, 2010
    • National Institutes of Health (NIH) - Pipeline By Therapeutic Class, 2010
    • National Institutes of Health (NIH) - Pipeline By Target, 2010
    • National Institutes of Health (NIH) - Pipeline By Route of Administration, 2010
    • National Institutes of Health (NIH) - Pipeline By Molecule Type, 2010
    • National Institutes of Health (NIH) - Dormant Developmental Projects, 2010
    • National Institutes of Health (NIH), Other Locations
    • National Institutes of Health (NIH), Deals Summary, 2004 to YTD 2010
    • National Institutes of Health (NIH), Deals Summary by Region, 2004 to YTD 2010
    • National Institutes of Health (NIH), Deals Summary, 2004 to YTD 2010
    • National Institutes of Health (NIH), Deals Summary, 2004 to YTD 2010
  • List of Figures
    • National Institutes of Health (NIH) - Pipeline by Therapy Area and Indication, 2010
    • National Institutes of Health (NIH) - Pipeline by Stage of Development, 2010
    • National Institutes of Health (NIH) - Monotherapy Products in Pipeline, 2010
    • National Institutes of Health (NIH) - Pipeline By Therapeutic Class, 2010
    • National Institutes of Health (NIH) - Pipeline By Target, 2010
    • National Institutes of Health (NIH) - Pipeline By Route of Administration, 2010
    • National Institutes of Health (NIH) - Pipeline By Molecule Type, 2010
+44 20 8816 8548

Ask a question about National Institutes of Health (NIH) - Developmental Therapeutics Review

Enter the characters you see in the picture below
Captcha